We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Finch Therapeutics Group Inc (FNCH) USD0.001

Sell:$2.54 Buy:$2.80 Change: $0.28 (9.86%)
NASDAQ:0.13%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$2.54
Buy:$2.80
Change: $0.28 (9.86%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$2.54
Buy:$2.80
Change: $0.28 (9.86%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 70 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The Company’s assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.

Contact details

Address:
75 State Street, Suite 100
BOSTON
02109
United States
Telephone:
+1 (617) 2296499
Website:
https://finchtherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
FNCH
ISIN:
US31773D2009
Market cap:
$4.65 million
Shares in issue:
1.61 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Matthew Blischak
    Chief Executive Officer
  • Lance Thibault
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.